ViCentra has expanded its Series D financing round to $98m, following the addition of $13m in new and existing investment to support European commercial growth and preparation for US market access of its Kaleido insulin patch pump system.

The latest funding includes new investment from ROM Utrecht Region and a consortium of Dutch investors including Venturing Tech, alongside increased participation from existing investor Innovation Industries. The round follows an $85m raise completed in September 2025.

ViCentra plans to use the additional capital to scale manufacturing and strengthen commercial operations across Germany, the Netherlands and France, while also advancing readiness for regulatory and commercial entry into the USA.

The company develops and commercialises Kaleido, a wearable insulin patch pump designed for people with diabetes requiring continuous insulin delivery. Kaleido is already available in several European markets, with adoption accelerating in Germany, the second largest insulin pump market globally.

Tom Arnold, chief executive officer of ViCentra, said the funding builds on a year of operational progress for the company.

“The past year has been transformative for ViCentra,” Arnold said. “This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands and France, and ensures that we remain on course for our planned US market access.”

He added: “Our goal for 2026 is clear: convert our current high demand into satisfied users through uncompromising quality and performance and nearly triple our European user base by the end of 2026.”

According to the company, ViCentra doubled its user base during 2025 to more than 4,000 people, alongside associated revenue growth. The expansion was supported by increased manufacturing capacity and broader uptake across multiple European markets.

The Kaleido system is positioned as a compact insulin patch pump, combining insulin delivery with design features intended to improve user experience. While competition in the insulin pump market continues to intensify, ViCentra is focusing on manufacturing scale, commercial execution and geographic expansion as it enters its next phase of growth.

The additional financing is expected to support continued expansion of ViCentra’s operational footprint in Europe, while enabling the company to progress regulatory and market preparation activities for the USA.